Iron Hydroxide Polymaltose
PreclinicalSmall molecule
Iron Hydroxide Polymaltose is one of 35 small molecule programs targeting Celiac Disease. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
52 competitors in Celiac Disease
#DrugCompanyPhaseTrials
1Tylenol
KKenvue Brands
Approved
Advil
KKenvue Brands
Approved
VIOKACE
DDigestive Care, Inc.
Approved
Sporanox
SSebela Pharmaceuticals Development LLC
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Iron
WWatson Pharmaceuticals
Approved
Ferinject
VVifor Pharma
Approved
Zocor
OOrganon and Co
Phase 3
Opzelura
PfizerPhase 2
Entyvio
TakedaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Iron Hydroxide Polymaltose. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- KKaplan Medical Center